Miki Kamiyama

Miki Kamiyama

Auto-generated profile, based on publicly available information

Miki Kamiyama

Heidelberg University 4 Laboratory of AngioRhythms, European Center for Angioscience (ECAS), Medical Faculty Mannheim Mannheim, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
MSMahak Singhal
Mahak Singhal
NGNicolas Gengenbacher
Nicolas Gengenbacher
APAshik Ahmed Abdul Pari
Ashik Ahmed Abdul Pari
MKMiki Kamiyama
Miki Kamiyama
LHLing Hai
Ling Hai
HAHellmut Augustin
Hellmut Augustin
A temporal systems biology screen of premetastatic endothelial cells identified LRG1 as a therapeutic target for restricting metastases.

1 December 2017 in Advances in Biological Regulation
Verified
Journal Article
Closed access
HRHiroki Ryuno
Hiroki Ryuno
INIsao Naguro
Isao Naguro
MKMiki Kamiyama
Miki Kamiyama

17 April 2020 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MSMahak Singhal
Mahak Singhal
NGNicolas Gengenbacher
Nicolas Gengenbacher
SPSilvia La Porta
Silvia La Porta
SGStephanie Gehrs
Stephanie Gehrs
JSJingjing Shi
Jingjing Shi
HAHellmut Augustin
Hellmut Augustin
The angiopoietin (Ang)–Tie pathway has been intensely pursued as candidate second‐generation anti‐angiogenic target. While much of the translational work has focused on the ligand Ang2, the clinical efficacy of Ang2‐targeting drugs is limited and failed to improve patient survival. In turn, the orphan receptor Tie1 remains therapeutically unexplored, although its endothelial‐specific genetic deletion has previously been shown to result in a strong reduction in metastatic growth. Here, we report a novel Tie1 function‐blocking antibody (AB‐Tie1‐39), which suppressed postnatal retinal angiogenesis. During primary tumor growth, neoadjuvant administration of AB‐Tie1‐39 strongly impeded systemic metastasis. Furthermore, the administration of AB‐Tie1‐39 in a perioperative therapeutic window led to a significant survival advantage as compared to control‐IgG‐treated mice. Additional in vivo experimental metastasis and in vitro transmigration assays concurrently revealed that AB‐Tie1‐39 treatment suppressed tumor cell extravasation at secondary sites. Taken together, the data phenocopy previous genetic work in endothelial Tie1 KO mice and thereby validate AB‐Tie1‐39 as a Tie1 function‐blocking antibody. The study establishes Tie1 as a therapeutic target for metastasis in a perioperative or neoadjuvant setting.

1 January 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
MKMiki Kamiyama
Miki Kamiyama
HAHellmut Augustin
Hellmut Augustin
Angiopoietin (ANPGT)–TIE signaling serves as a critical regulator of vessel maturation controlling vascular quiescence, maintenance, and homeostasis (primarily through ANGPT1–TIE2 signaling), as well as enabling vascular plasticity and responsiveness to exogenous cytokines (primarily through antagonistically acting ANGPT2). An alternatively spliced form of ANGPT2 (ANGPT2443) was first reported 20 years ago. Yet, little is known to this day about its biological functions. In this issue of Cancer Research, Kapiainen and colleagues report an elegant series of experiments adding to the complexity and contextuality of ANGPT–TIE signaling. The authors studied the function of ANGPT2443 in cellular experiments as well as in a genetic model in vivo, revealing that it is proteolytically cleaved into a lower molecular weight isoform (termed ANGPT2DAP) that lacks the superclustering domain necessary for multimer formation. When compared with full-length ANGPT2, ANGPT2443 and ANGPT2DAP showed lower binding affinity to α5β1 integrin, but were more potent inhibitors of ANGPT1–TIE2 signaling. Functionally, ANGPT2443 impaired vessel enlargement and vein morphogenesis during postnatal retinal angiogenesis. Tumor experiments in Angpt2443-expressing mice showed enhanced destabilization of the lung vasculature, with varying effects on metastasis. Taken together, the study provides important insight into the significance of ANGPT2 alternative splicing and identifies ANGPT2443 and ANGPT2DAP as a biological rheostat of ANGPT1–TIE2 signaling. Future work will need to characterize the relative ratios and functional contributions of the ANGPT2 variants in different pathophysiologic settings.See related article by Kapiainen et al., p. 129

10 February 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
MFMakoto Fujimoto
Makoto Fujimoto
MKMiki Kamiyama
Miki Kamiyama
KFKosuke Fuse
Kosuke Fuse
HRHiroki Ryuno
Hiroki Ryuno
TOTakeru Odawara
Takeru Odawara
HIHidenori Ichijo
Hidenori Ichijo
Tumor metastasis is the leading cause of death worldwide and involves an extremely complex process composed of multiple steps. Our previous study demonstrated that apoptosis signal‐regulating kinase 1 (ASK1) deficiency in mice attenuates tumor metastasis in an experimental lung metastasis model. However, the steps of tumor metastasis regulated by ASK1 remain unclear. Here, we showed that ASK1 deficiency in mice promotes natural killer (NK) cell‐mediated intravascular tumor cell clearance in the initial hours of metastasis. In response to tumor inoculation, ASK1 deficiency upregulated immune response‐related genes, including interferon‐gamma (IFNγ). We also revealed that NK cells are required for these anti‐metastatic phenotypes. ASK1 deficiency augmented cytokine production chemoattractive to NK cells possibly through induction of the ligand for NKG2D, a key activating receptor of NK cells, leading to further recruitment of NK cells into the lung. These results indicate that ASK1 negatively regulates NK cell‐dependent anti‐tumor immunity and that ASK1‐targeted therapy can provide a new tool for cancer immunotherapy to overcome tumor metastasis.

20 July 2026 in Cancer Discovery
Verified
Journal Article
Open access
XZXiaowen Zhang
Xiaowen Zhang
MKMiki Kamiyama
Miki Kamiyama
MTMargaret Tulessin
Margaret Tulessin
LRLorna Rinck
Lorna Rinck
JMJan-Philipp Mallm
Jan-Philipp Mallm
HAHellmut Augustin
Hellmut Augustin
Combination therapies involving vascular targeting drugs have shown promise in overcoming resistance to immunotherapy. However, the prerequisite for vascular modulation to evoke an effective antitumor T-cell response remains elusive. Tracing the transcriptional response of liver metastasis–associated peritumoral and tumor endothelial cells (TEC) to T-cell intervention, we discovered an immunomodulatory TEC subpopulation that highly expressed lipoprotein lipase (LPL). LPL+ TECs facilitated intratumoral homing of activated antitumor CD8+ T cells driving liver metastatic regression. Mechanistically, LPL enhanced MHC-I–dependent cross-presentation of tumor antigens on TECs for T-cell trafficking. Consequently, LPL+ TECs were recognized and targeted by T cells, further aiding antitumor response. Corresponding analyses of human liver metastasis samples identified a significant correlation between the presence of intratumoral LPL+ blood vessels and the accumulation of T cells. Altogether, the study identifies a decisive role of TECs in orchestrating an effective T-cell response by overcoming tumor’s intrinsic insufficient antigen presentation. Significance: The study identifies LPL+ TECs as orchestrators of activated CD8+ T-cell homing into immunologically cold tumors with low baseline MHC-I expression. Enhancing tumor antigen exposure by MHC-I cross-presentation in TECs presents a promising approach to compensate the intrinsic inability of tumor cells and boost antitumor immunotherapy.